Diabetes resolution following discontinuation of a second-generation antipsychotic: Three cases

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 4, 2013, Pages 202-203

  Strassnig, Martin ^a   Awerbuck, Jon ^b   Ganguli, Rohan ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; RISPERIDONE; TRIACYLGLYCEROL;

ABORIGINE; ADULT; AMENORRHEA; ARTICLE; BLOOD GLUCOSE METER; CANADA; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DISEASE DURATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-IV; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; WITHHOLDING TREATMENT;

EID: 84873575768     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.STAW.01062013     Document Type: Article

References (15)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150(6):1115-1121.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64(10):1123-1131.
3. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-1711.
4. De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006;29:2329-2330.
5. Koller EA, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001;111:716-723.
6. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacother 2002;22:842-842.
7. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16:63-73.
8. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001;14:278-282.
9. Tovey E, Rampes H, Livingstone C. Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 2005;19(2):207-210.
10. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 Suppl 1:1-93.
11. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-424.
12. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al.; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71-93.
13. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86(1-3):15-22.
14. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166(3):345-353.
15. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67(1):17-24.